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Introduction
Management of head and neck cancer is organized in a fairly unified and
centralized manner in the five Northern European countries with a population
of 27 M people [1]. However, there are no consensus-based site-specific
treatment protocols for these tumours in this region although national
guidelines exist. Furthermore, guidelines should be created for rare cancers to
enable prospective collection of data from multicentre studies.
Nasopharyngeal cancer (NPC) is a rather uncommon malignancy in the
Western world. NPC incidence varies greatly between continents, and
disparities exist even among specific Asian American populations [2]. The
Nordic Countries, i.e. Denmark, Finland, Iceland, Norway, and Sweden
remain a low-incidence region with age-standardized incidence rates of 0.2
and 0.3/100,000 for females and males, respectively, during 2010-2014 [3].
NPC is highly sensitive to both radiotherapy (RT) and chemotherapy (CT).
Thus, concurrent chemoradiotherapy (CRT) remains the standard treatment
for loco-regionally advanced NPC, i.e. conventional fractionated RT with
concurrent cisplatin and 5-FU, with or without adjuvant CT. The role of
adjuvant cisplatin and fluorouracil (PF) following CRT remains debatable [4].
Results from a recent meta-analysis confirm that the addition of concomitant
CT to RT significantly improves survival in this patient population [5].
However, there are preliminary results also of changing to an induction-
concurrent sequence, but the benefit of this protocol still remains uncertain
[6]. Further, intensity-modulated RT (IMRT) has been reported to provide an
improved loco-regional recurrence-free survival in both early and advanced
loco-regional NPC compared with 2D-CRT [7]. Also, in dosimetric
comparisons, intensity-modulated proton therapy (IMPT) seems to have the
potential to reduce dose to organs at risk when compared with IMRT and with
excellent loco-regional control rates [8]. Randomized prospective trials directly
comparing these two RT techniques are, however, lacking.
Early results of robotic nasopharyngectomy have shown a high local control
rate. Further, operating time seems to be comparable to open surgery and
postoperative morbidity rates remain low [9]. Currently, in some regions,
quantification of plasma EBV DNA is routinely used for monitoring patients
with NPC and predicting outcome of treatment [10]. The prognosis of NPC
has improved significantly over the past three decades because of advances
in various aspects of disease management as indicated above [4].
No previous report has evaluated the current treatment protocols and
outcome of NPC in Northern Europe. The aim of this Nordic collaborative
study was to obtain population-based data on the current management
strategies and outcome of NPC in the five Nordic countries.
Patients and Methods
Patients
This study consists of all patients with a NPC diagnosed and treated between
January 1, 2005 and December 31, 2009 at the 23 Nordic centres located in
Denmark, Finland, Iceland, Norway, and Sweden managing these patients.
The hospital records were reviewed to collect details about age, sex, tumour
histology (WHO criteria), TNM classification, stage, intent of treatment, details
of treatment (radiotherapy [RT], chemotherapy, [CT], and chemoradiotherapy
[CRT], neck dissection [ND]), tumour recurrence, and tumour and vital status
at the last follow up.
The study cohort consists of 358 consecutive patients. Complete medical
records from 344 (96.1%) patients were available for the analysis. The
median age was 57 years (range, 15 to 98), and 241 (70.1%) of the 344
patients were male. Tumour WHO criteria for the histological grade of
differentiation were as follows: I 11%, II 35%, III 45%. The stage distribution of
the cancers was as follows: I 7.5%, II 16.2%, III 33.5%, IVa 27.1%, IVb 7%,
and IVc 7%. All patients had a minimum follow-up time of three years or until
death.
The national and/or institutional authorities approved the study protocol in
each participating country.
Statistical analysis
Survival was analysed with the Kaplan-Meier product-limit method. Overall
survival was calculated from the date of the diagnosis of NPC to the date of
death from any cause, censoring the patients who were alive on the date of
the last contact. Disease-specific survival was calculated from the date of the
diagnosis to death considered to result from NPC, censoring the patients who
were alive and those who had died from a competing cause on the date of
death. Loco-regional survival was calculated from the date of the diagnosis to
the date of cancer recurrence in the locoregional region or to death, censoring
the patients who were alive without locoregional recurrence.
Results
Eighty-eight percent of the 344 patients were treated with curative intent. The
used RT technique was 3D-CRT for 181 (52.6%) and IMRT for 163 (47.4%)
patients. In IMRT, the simultaneous integrated boost (SIB) technique was
used for 21 patients. Seventeen (5%) of the 344 patients received a
brachytherapy boost after RT. Proton therapy was given as the primary
treatment in two cases: one patient received definitive proton therapy, and
one had RT boosted with protons.
A high (≥70 Gy), intermediate (65-69 Gy), and low cumulative dose (<65 Gy)
of RT was given to 107 (31.2%), 183 (53.2%), and 43 (12.5%) patients,
respectively (data missing for 11 patients). Seventeen (5%) patients had
hyperfractionated treatment. Concurrent CT was given to 228 (66.3%) out of
the 344 patients. Seventy-two (20.9%) patients received CRT with cisplatin
100 mg/m2 every third week, and 154 (44.8%) patients cisplatin 40 mg/m2
once a week. Nimorazole combined with accelerated RT was administered to
5 patients at one centre.
Neoadjuvant CT was given to 82 (23.8%) and adjuvant CT to 26 (7.6%) of the
344 patients. In most patients, adjuvant CT consisted of three cycles of
cisplatin and fluorouracil. Other combinations used were carboplatin-
gemcitabine (n=7), cisplatin plus docetaxel (n=4), docetaxel (n=2) and
paclitaxel for one patient. Neck dissection was performed primarily in 16
(4.7%) cases, and as salvage surgery in 18 (5.2%) cases.
Fifty-five (16%) patients had a local recurrence, 34 (9.9 %) neck recurrence,
and 65 (18.9%) distant recurrence. At the end of follow-up, 172 (50%) patients
had no evidence of disease, 13 (3.8%) were alive with disease, 115 (33.4%)
had died of disease, and 39 (11.3%) of other causes. The 3-year and 5-year
survival estimates, respectively, were 77.9% (SE ± 2.6) and 60.2% (SE ± 3.4) for
overall survival, 82.8% (SE ± 2.4) and 66.4% (SE ± 3.4) for disease-specific
survival, and 78.9% (SE ± 2.6) and 70,7% (SE ± 3.1) for loco-regional tumour
control (Figure 1).
Discussion
Northern Europe, i.e. the five Nordic countries forms a culturally homogenous
region with a population of 27 M people and with similar organizational setting
for health care. However, this region still has no unified treatment protocol for
the management of head and neck cancer [1]. The Scandinavian Society for
Head and Neck Oncology (www.sshno.org) has the aim to harmonize the
current guidelines for various head and neck cancers in this region, and NPC
as a rare cancer type was chosen as one of the sites to be addressed for this
purpose. Here, we describe the treatment approach for nasopharyngeal
cancer at the 23 university hospitals which are responsible for the
management of this disease.
The present survey revealed that the treatment guidelines for NPC do vary
between the academic centres in the region. Differences in radiotherapy
techniques, concomitant chemotherapy and also in adjuvant chemotherapy
were observed. The general prescription of CRT, however, was in accordance
with the stage distribution of the study population as 67.6% had locally
advanced stage III or IV disease, and 66.2% received CRT.
These numbers are in line with the existing guidelines for the management of
NPC. Recent publications highlight IMRT, with or without concurrent
chemotherapy, as the mainstay of curative treatment, with concurrent CT for
stage III and IV disease [11] [12]. In this respect, the results of the present
survey warrant further development of the treatment guidelines in the
Northern Europe, since some variation was observed.
Reports on the outcome for NPC in the Northern Europe are rare. The results
on survival outcome in the present study may be compared to international
data gathered from randomized trials [5]. This comparison shows a slightly
lower overall survival rate in our study, but equivalent disease-
specific/progression-free survival rates. It needs to be emphasized, though,
that the present study was population-based and included all patients with
NPC without restrictions, whereas the selection criteria for phase III trials
favour patients with good performance status.
Unified treatment guidelines for NPC in the Nordic countries should be made
to facilitate improving survival outcomes and to reduce treatment-associated
morbidity. The health care organizations in the Nordic countries are rather
similar, mainly funded by central governments and run by public hospitals,
particularly considering cancer treatment. Additionally, all the Nordic countries
have population-based cancer registries. This common structure should
facilitate implementation of standard logistics and general treatment
strategies, including clinical guidelines for rare cancer diseases such as NPC.
It remains obvious that centralization of the treatment of rare cancers should
be further pursued. Although management of head and neck cancer, in
general, is centralized to the university hospitals in all of these countries,
some of the centres manage only one to three NPC cases annually. Due to
this small number of NPC patients in the Nordic countries, means to improve
the treating team experience should be actively sought.
Conclusions
NPC is a relatively rare type of head and neck cancer in the Nordic countries.
Management protocol for this disease varies between centres responsible for
its treatment in this area despite a common public health care structure. The
results from this survey indicate that the outcome results of NPC in this region
compare well with the results available from other regions, but further benefits
might be obtained from mutually agreed detailed treatment guidelines.
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Figure Legend:
Figure 1. Overall survival (A), disease-specific (B) and loco-regional survival
(C) in a series of 344 patients with nasopharyngeal cancer in Northern Europe
during the years 2005-2009.
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